Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01491932 · ClinicalTrials.gov registry record · Phase 2

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

A Phase 2 study of Parkinson Disease and Movement Disorders, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
129
Enrollment target
20
Study locations

NCT01491932 is a Phase 2 study of Parkinson Disease and Movement Disorders that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 129 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01491932, a Phase 2 study of Parkinson Disease and Movement Disorders, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
129 participants
Enrollment target
20
Study locations

Study Summary

This study is to evaluate long-term safety, tolerability and efficacy for AFQ056 in patients who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias (PD-LID).

Conditions Studied

Parkinson Disease Movement Disorders Dyskinesias Parkinsonian Disorders Anti-Dyskinesia Agents

Interventions

  • DRUG AFQ056

Study Locations (20)

Other

  • Novartis Investigative Site - Innsbruck
  • Novartis Investigative Site - Linz
  • Novartis Investigative Site - Vienna
  • Novartis Investigative Site - Clermont-Ferrand
  • Novartis Investigative Site - Lille
  • Novartis Investigative Site - Pessac
  • Novartis Investigative Site - Beelitz-Heilstätten
  • Novartis Investigative Site - Berlin
  • Novartis Investigative Site - Bochum
  • Novartis Investigative Site - Kassel
  • Novartis Investigative Site - Leipzig
  • Novartis Investigative Site - München
  • Novartis Investigative Site - Stadtroda
  • Novartis Investigative Site - Westerstede/Oldenburg
  • Novartis Investigative Site - Kaposvár
  • Novartis Investigative Site - Szeged

Colorado

  • Novartis Investigative Site - Englewood

Kansas

  • Novartis Investigative Site - Kansas City

Wisconsin

  • Novartis Investigative Site - Milwaukee

Ontario

  • Novartis Investigative Site - London

Trial Details

FieldValue
Enrollment Target 129 participants
Start Date 2012-03
Est. Completion 2013-10
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01491932

The ClinicalTrials.gov registry entry for NCT01491932 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which AFQ056 is the first listed.

NCT01491932 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, Colorado, Kansas.

Frequently Asked Questions

What is clinical trial NCT01491932 about?

NCT01491932 is a clinical study titled "Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias". This study is to evaluate long-term safety, tolerability and efficacy for AFQ056 in patients who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias (PD-LID).

What is the current status of trial NCT01491932?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2012-03. Estimated completion is 2013-10.

What conditions does trial NCT01491932 study?

This clinical trial studies the following conditions: Parkinson Disease, Movement Disorders, Dyskinesias, Parkinsonian Disorders, Anti-Dyskinesia Agents.

What interventions are being tested in trial NCT01491932?

The interventions under investigation include: AFQ056 (DRUG).

Who is sponsoring clinical trial NCT01491932?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01491932 being conducted?

This trial has 20 study locations across Colorado, Kansas, Wisconsin, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

Movement Disorders

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.